Please use this identifier to cite or link to this item:
|Title:||A randomized controlled pilot study of Pentoxifylline in patients with non-alcoholic steatohepatitis (NASH)||Authors:||Lee, Y.-M.
Randomized controlled study
|Issue Date:||Jun-2008||Citation:||Lee, Y.-M., Sutedja, D.S., Wai, C.-T., Dan, Y.-Y., Aung, M.-O., Zhou, L., Cheng, C.-L., Wee, A., Lim, S.-G. (2008-06). A randomized controlled pilot study of Pentoxifylline in patients with non-alcoholic steatohepatitis (NASH). Hepatology International 2 (2) : 196-201. ScholarBank@NUS Repository. https://doi.org/10.1007/s12072-008-9058-1||Abstract:||Purpose: Tumor necrosis factor-α (TNF-α) is implicated in non-alcoholic steatohepatitis (NASH). Pentoxifylline inhibits TNF-α. We wanted to evaluate the efficacy of Pentoxifylline on NASH patients. Methods: Patients with biopsy proven NASH and persistently elevated alanine aminotransferase (ALT) greater than 1.5 times the upper limit of normal were randomized to 3 months of treatment with a step 1 American Heart Association diet and daily exercise with Pentoxifylline or placebo. Liver function tests, serum lipids and TNF-α, Interleukin 6 (IL-6), and plasma hyaluronic acid were measured at baseline, at weeks 6 and 12. Categorical data were analyzed by Fisher's exact test while independent sample t-test and Mann-Whitney test were used for continuous data. Results: Eleven patients were randomized into the Pentoxifylline and nine to the placebo group. After 3 months of treatment body mass index (BMI), ALT and aspartate aminotransferase (AST) decreased significantly in both groups. There was no difference between the two groups in reduction of BMI (P = 0.897). There was significantly greater reduction in AST in the Pentoxifylline group (P = 0.038). There was a trend toward lower ALT level (P = 0.065) in the Pentoxifylline group. TNF-α and IL-6 decreased significantly in both groups after treatment, but there was no significant difference between the two groups. Conclusion: Three months of Pentoxifylline treatment in combination with diet and exercise results in significantly greater reduction in AST levels in patients with NASH as compared with controls. © Asian Pacific Association for the Study of the Liver 2008.||Source Title:||Hepatology International||URI:||http://scholarbank.nus.edu.sg/handle/10635/129746||ISSN:||19360533||DOI:||10.1007/s12072-008-9058-1|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.